Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
8.18
-0.10 (-1.21%)
At close: Feb 21, 2025, 4:00 PM
8.33
+0.15 (1.83%)
After-hours: Feb 21, 2025, 6:19 PM EST
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
99.63M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CRBP News
- 8 days ago - CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 - GlobeNewsWire
- 11 days ago - Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU - GlobeNewsWire
- 25 days ago - Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 6 weeks ago - Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors - GlobeNewsWire
- 2 months ago - FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies - Seeking Alpha
- 4 months ago - Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire